Guizhou Xinbang Pharmaceutical Co., Ltd. - Laporan Laba Rugi (TTM)

Guizhou Xinbang Pharmaceutical Co., Ltd.
CN ˙ SZSE ˙ CNE100000NG5
CN¥ 3.65 ↑0.01 (0.27%)
2025-09-05
BAHAGING PRESYO
Laporan Laba Rugi (TTM)

Laporan Laba Rugi Guizhou Xinbang Pharmaceutical Co., Ltd. menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.

Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.

2020
09-30
2020
12-31
2021
03-31
2021
06-30
2021
09-30
2022
01-01
2022
03-31
2022
06-30
2022
09-30
2023
01-01
2023
03-31
2023
06-30
2023
09-30
2023
12-31
2024
03-31
2024
06-30
2024
09-30
2024
12-31
2025
03-31
2025
06-30
Revenue 5,916 5,846 6,060 6,241 6,289 6,472 6,590 6,517 6,435 6,350 6,377 6,463 6,487 6,461 6,438 6,251 6,203 6,032 5,891 5,831
Change (%) -1.20 3.67 2.99 0.77 2.91 1.83 -1.11 -1.26 -1.32 0.42 1.35 0.37 -0.40 -0.35 -2.91 -0.77 -2.75 -2.34 -1.02
% of Revenue 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost Of Sales 4,624 4,594 4,697 4,878 4,948 5,119 5,239 5,171 5,127 5,133 5,175 5,243 5,255 5,240 5,233 5,119 5,103 5,000 4,903 4,852
Change (%) -0.64 2.25 3.85 1.43 3.47 2.34 -1.30 -0.86 0.12 0.82 1.31 0.23 -0.28 -0.13 -2.17 -0.31 -2.02 -1.96 -1.03
% of Revenue 78.15 78.59 77.51 78.16 78.67 79.10 79.50 79.35 79.67 80.84 81.16 81.12 81.00 81.10 81.28 81.90 82.27 82.89 83.22 83.22
Gross Operating Profit 1,293 1,252 1,363 1,363 1,341 1,352 1,351 1,346 1,308 1,217 1,202 1,220 1,232 1,221 1,205 1,132 1,100 1,032 988 978
Change (%) -3.18 8.88 0.02 -1.60 0.84 -0.11 -0.37 -2.81 -6.97 -1.26 1.55 1.00 -0.92 -1.29 -6.12 -2.83 -6.15 -4.21 -1.01
% of Revenue 21.85 21.41 22.49 21.84 21.33 20.90 20.50 20.65 20.33 19.16 18.84 18.88 19.00 18.90 18.72 18.10 17.73 17.11 16.78 16.78
SG&A 829 813 787 806 822 793 802 827 813 855 859 826 816 803 784 764 766 719 696 676
Change (%) -1.91 -3.27 2.44 2.01 -3.53 1.14 3.02 -1.61 5.10 0.54 -3.90 -1.15 -1.66 -2.39 -2.52 0.23 -6.03 -3.28 -2.89
% of Revenue 14.02 13.92 12.98 12.92 13.08 12.26 12.18 12.68 12.64 13.46 13.48 12.78 12.58 12.43 12.17 12.22 12.34 11.93 11.81 11.59
R&D 23 11 3 2 1 2 2 1 2 1 2 3 3 5 5 5 6 5 4 5
Change (%) -54.64 -71.70 -35.57 -57.67 137.66 -15.55 -21.02 27.09 -26.51 45.79 48.02 7.62 66.68 3.73 6.49 24.96 -28.89 -3.40 22.80
% of Revenue 0.39 0.18 0.05 0.03 0.01 0.03 0.02 0.02 0.03 0.02 0.03 0.04 0.04 0.07 0.08 0.08 0.10 0.08 0.08 0.09
OpEx 5,505 5,442 5,507 5,707 5,795 5,943 6,077 6,031 5,974 6,017 6,065 6,100 6,102 6,070 6,044 5,912 5,900 5,749 5,629 5,558
Change (%) -1.15 1.20 3.63 1.54 2.55 2.25 -0.75 -0.94 0.72 0.79 0.58 0.04 -0.53 -0.43 -2.18 -0.21 -2.56 -2.10 -1.26
% of Revenue 93.05 93.10 90.88 91.44 92.15 91.83 92.21 92.54 92.84 94.76 95.10 94.38 94.07 93.95 93.88 94.58 95.12 95.31 95.55 95.33
Operating Income 411 404 553 534 494 529 513 486 461 333 312 363 385 391 394 339 303 283 262 273
Change (%) -1.79 36.93 -3.38 -7.52 7.02 -2.93 -5.28 -5.20 -27.75 -6.20 16.30 6.03 1.59 0.81 -14.13 -10.55 -6.59 -7.28 3.95
% of Revenue 6.95 6.90 9.12 8.56 7.85 8.17 7.79 7.46 7.16 5.24 4.90 5.62 5.93 6.05 6.12 5.42 4.88 4.69 4.45 4.67
Interest Expense -143 -100 -127 -125 -101 -100 -83 -57 -53 -52 -50 -43 -37 -40 -33 -31 -26 -24 -23 -21
Change (%) -30.55 27.52 -1.99 -18.83 -0.86 -17.01 -31.71 -6.26 -2.70 -2.99 -15.11 -13.95 8.17 -18.08 -5.52 -15.70 -9.13 -3.71 -5.62
% of Revenue -2.42 -1.70 -2.10 -1.99 -1.61 -1.55 -1.26 -0.87 -0.83 -0.82 -0.79 -0.66 -0.57 -0.61 -0.51 -0.49 -0.42 -0.39 -0.38 -0.37
Net Income 159 174 259 290 260 273 274 252 304 224 204 249 230 287 293 246 217 101 84 94
Change (%) 8.89 49.10 12.25 -10.33 4.79 0.47 -8.18 20.69 -26.15 -9.15 22.10 -7.63 24.93 2.05 -16.04 -11.72 -53.33 -17.34 11.81
% of Revenue 2.69 2.97 4.27 4.65 4.14 4.22 4.16 3.86 4.72 3.53 3.20 3.85 3.54 4.45 4.55 3.94 3.50 1.68 1.42 1.61

Source: Capital IQ

Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista